ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Gyre Therapeutics Inc

Gyre Therapeutics Inc (GYRE)

11.44
-0.16
( -1.38% )
Updated: 02:13:11

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
11.44
Bid
11.30
Offer
11.68
Volume
19,259
11.309 Day's Range 11.8541
8.26 52 Week Range 22.00
Market Cap
Previous Close
11.60
Open
11.70
Last Trade
5
@
11.49
Last Trade Time
02:13:26
Financial Volume
US$ 222,007
VWAP
11.5275
Average Volume (3m)
93,014
Shares Outstanding
93,521,434
Dividend Yield
-
PE Ratio
-11.56
Earnings Per Share (EPS)
-0.99
Revenue
113.45M
Net Profit
-92.93M

About Gyre Therapeutics Inc

Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalc... Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Gyre Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GYRE. The last closing price for Gyre Therapeutics was US$11.60. Over the last year, Gyre Therapeutics shares have traded in a share price range of US$ 8.26 to US$ 22.00.

Gyre Therapeutics currently has 93,521,434 shares in issue. The market capitalisation of Gyre Therapeutics is US$1.08 billion. Gyre Therapeutics has a price to earnings ratio (PE ratio) of -11.56.

GYRE Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.11-0.95238095238111.5511.9710.2926037411.19969281CS
40.0450.39491004826711.39513.0710.2925116111.85541345CS
12-0.115-0.99524015577711.55514.42289.519301411.03076741CS
26-2.355-17.071402682113.795199.517793011.98053846CS
52-10.01-46.666666666721.45228.267005012.79315796CS
1564.4463.4285714286730.45.888084815.05223423CS
2604.4463.4285714286730.45.888084815.05223423CS

GYRE - Frequently Asked Questions (FAQ)

What is the current Gyre Therapeutics share price?
The current share price of Gyre Therapeutics is US$ 11.44
How many Gyre Therapeutics shares are in issue?
Gyre Therapeutics has 93,521,434 shares in issue
What is the market cap of Gyre Therapeutics?
The market capitalisation of Gyre Therapeutics is USD 1.08B
What is the 1 year trading range for Gyre Therapeutics share price?
Gyre Therapeutics has traded in the range of US$ 8.26 to US$ 22.00 during the past year
What is the PE ratio of Gyre Therapeutics?
The price to earnings ratio of Gyre Therapeutics is -11.56
What is the cash to sales ratio of Gyre Therapeutics?
The cash to sales ratio of Gyre Therapeutics is 9.47
What is the reporting currency for Gyre Therapeutics?
Gyre Therapeutics reports financial results in USD
What is the latest annual turnover for Gyre Therapeutics?
The latest annual turnover of Gyre Therapeutics is USD 113.45M
What is the latest annual profit for Gyre Therapeutics?
The latest annual profit of Gyre Therapeutics is USD -92.93M
What is the registered address of Gyre Therapeutics?
The registered address for Gyre Therapeutics is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Gyre Therapeutics website address?
The website address for Gyre Therapeutics is www.gyretx.com
Which industry sector does Gyre Therapeutics operate in?
Gyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTOGBit Origin Ltd
US$ 0.643599
(253.63%)
136.49M
BTAIBioXcel Therapeutics Inc
US$ 5.035
(133.10%)
32.32M
ACONAclarion Inc
US$ 5.61
(67.46%)
40.04M
FTFTFuture FinTech Group Inc
US$ 0.33
(63.37%)
168.53M
NAMIJinxin Technology Holding Company
US$ 3.5357
(35.47%)
367.97k
BLNEEastside Distilling Inc
US$ 0.7537
(-90.18%)
10.61k
AGMHAGM Group Holdings Inc
US$ 0.1427
(-56.57%)
2.53M
NVNINVNI Group Ltd
US$ 0.513
(-49.21%)
16.68M
SYRSSyros Pharmaceuticals Inc
US$ 0.0784
(-45.25%)
4.69M
SPGCSacks Parente Golf Inc
US$ 0.1162
(-44.30%)
24.31M
FTFTFuture FinTech Group Inc
US$ 0.33
(63.37%)
168.53M
BTOGBit Origin Ltd
US$ 0.643599
(253.63%)
136.49M
NVDANVIDIA Corporation
US$ 119.10
(-4.66%)
62.23M
TRNRInteractive Strength Inc
US$ 3.475
(35.21%)
52.61M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13.77
(2.38%)
48.05M

Your Recent History

Delayed Upgrade Clock